Top

Published in:

01-12-2004 | Review

Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck

Authors: Thomas K. Hoffmann, Henning Bier, Theresa L. Whiteside

Published in: Cancer Immunology, Immunotherapy | Issue 12/2004

Abstract

Despite advances in surgery, radiotherapy, and chemotherapy, the overall survival rates for patients with squamous cell carcinoma of the head and neck (SCCHN) have not changed over the last decades. Clearly, novel therapeutic strategies are needed for this cancer, which is highly immunosuppressive. Therefore, biologic therapies able to induce and/or up-regulate antitumor immune responses could represent a complementary approach to conventional treatments. Because patients with SCCHN are frequently immunocompromised due to the elimination or dysfunction of critical effector cells of the immune system, it might be necessary to restore these immune functions to allow for the generation of more effective antitumor host responses. Simultaneously, to prevent tumor escape, it might be necessary to alter attributes of the malignant cells. The present review summarizes recent advances in the field of immunotherapy of SCCHN, including techniques of nonspecific immune stimulation, the use of monoclonal antibodies, advances in adoptive immunotherapy and genetic engineering, as well as anticancer vaccines. These biologic therapies, alone or in combination with conventional treatment, are likely to develop into useful future treatment options for patients with SCCHN.

Reichert TE, Rabinowich H, Johnson JT, Whiteside TL (1998) Immune cells in the tumor microenvironment. Mechanism responsible for signaling and functional defects. J Immunother 21: 295PubMed

Whiteside TL (2002) Tumor-induced death of immune cells: its mechanisms and consequences. Semin Cancer Biol 12:43CrossRefPubMed

Hadden JW (1997) The immunopharmacology of head and neck cancer: an update. Int J Immunopharmacol 19:629CrossRefPubMed

Richtsmeier WJ (1988) Interferon gamma induced oncolysis: an effect on head and neck squamous carcinoma. Arch Otolaryngol Head Neck Surg 114: 432PubMed

Whiteside TL, Rabinowich H (1998) The role of Fas/FasL in immunosuppression induced by human tumors. Cancer Immunol Immunother 46:175PubMed

Whiteside TL (1999) Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 48:346PubMed

Whiteside TL (2001) Immunobiology and immunotherapy of head and neck cancer. Curr Oncol Rep 3:46PubMed

Wanebo HJ, Oettgen HF, Mike V, Pinsky CM, Strong EW, Hilal EY (1978) Adjuvant trial of levamisole in patients with squamous cell cancer of the head and neck: a preliminary report. Recent Results Cancer Res 68:324PubMed

Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2003) Imbalance in absolute counts of T lymphocyte subsets in patients with head and neck cancer and its relation to disease. J Cancer Res Clin Oncol 129:S45

10.

Rice SQ, Crane IJ, Scully C, Prime SS (1992) Production of a suppressor of lymphocyte proliferation by two human oral carcinoma cell lines. Scand J Immunol 36:443PubMed

11.

Berlinger NT (1984) Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins. Laryngoscope 94:1407PubMed

12.

Snyderman CH, Klapan I, Milanovich M, Heo DS, Wagner R, Schwartz D, Johnson JT, Whiteside TL (1994) Comparison of in vivo and in vitro prostaglandin E2 production by squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 111:189

13.

Maca RD (1983) The effects of prostaglandins on the proliferation of cultured human T lymphocytes. Immunopharmacology 6:267CrossRefPubMed

14.

LaPointe H, Lampe H, Banerjee D (1992) Head and neck squamous cell carcinoma cell line—induced suppression of in vitro lymphocyte proliferative responses. Arch Otolaryngol Head Neck Surg 106:149

15.

Wanebo HJ, Riley T, Katz D, Pace RC, Johns ME, Cantrell RW (1988) Indomethacin sensitive suppressor cell activity in head and neck cancer patients: the role of the adherent mononuclear cell. Cancer 61:462PubMed

16.

Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ, Uyemura K (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240PubMed

17.

Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS, Weissler MC (1995) Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of the head and neck. Otolaryngol Head Neck Surg 113:541PubMed

18.

Simons PJ, Oostendorp RA, Tas MP, Drexhage HA (1994) Comparison of retroviral p15E-related factors and interferon alpha in head and neck cancer. Cancer Immunol Immunother 38:178CrossRefPubMed

19.

Tan IB, Drexhage HA, Mullink R, Hensen-Logmans S, De Haan-Meulman M, Snow GB, Balm AJ (1987) Immunohistochemical detection of retroviral-p15E-related material in carcinomas of the head and neck. Arch Otolaryngol Head Neck Surg 96:251

20.

Young MR, Wright MA, Lozano Y, Methews JP, Benefield J, Prechel MM (1996) Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer 67:333PubMed

21.

Bugis SP, Lotzova E, Savage HE, Hester JP, Racz T, Sacks PG, Schantz SP (1990) Inhibition of lymphokine-activated killer cell generation by blocking factors in sera of patients with head and neck cancer. Cancer Immunol Immunother 31:176PubMed

22.

Schantz SP, Savage HE, Brown BW, Young G, Liu FJ, Reger G, Newman RA (1990) The significance of C1q binding macromolecules within the head and neck cancer patient. Cancer Res 50:4349PubMed

23.

Gastman BR, Johnson DE, Whiteside TL, Rabinowich H (2000) Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 95:2015PubMed

24.

Kim J-W, Wieckowski E, Taylor D, Reichert TE, Whiteside T (2003) FaL-containing microvesicles in the circulation of patients with cancer induce apoptosis of activated T lymphocytes. J Immunother 26:S44

25.

Hoffmann TK, Dworacki G, Tsukishiro T, Meidenbauer N, Gooding B, Johnson J, Whiteside TL (2002) Spontanous apoptosis of circulating CD8+ T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Research 8:2553

26.

Hoffmann TK, Müller-Berghaus J, Ferris R, Johnson J, Storkus W, Whiteside TL (2002) Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res 8:1787PubMed

27.

Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL (2002) Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 8:3137PubMed

28.

Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL (1999) Spontanous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5:1263PubMed

29.

Tas MP, Simons PJ, Balm FJ, Drexhage HA (1993) Depressed monocyte polarization and clustering of dendritic cells in patients with head and neck cancer: in vitro restoration of this immunosuppression by thymic hormones. Cancer Immunol Immunother 36:108PubMed

30.

Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI (2000) Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6:1755PubMed

31.

Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI (2001) Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166:678PubMed

32.

Lathers DM, Achille N, Kolesiak K, Hulett K, Sparano A, Petruzzelli GJ, Young MR (2001) Increased levels of immune inhibitory CD34+ progenitor cells in the peripheral blood of patients with node positive head and neck squamous cell carcinomas and the ability of these CD34+ cells to differentiate into immune stimulatory dendritic cells. Otolaryngol Head Neck Surg 125:205CrossRefPubMed

33.

Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR (1995) Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res 1:95PubMed

34.

Lang S, Whiteside TL, Lebeau A, Zeidler R, Mack B, Wollenberg B (1999) Impairment of T-cell activation in head and neck cancer in situ and in vitro: strategies for an immune restoration. Arch Otolaryngol Head Neck Surg 125:82

35.

Vora AR, Rodgers S, Parker AJ, Start R, Rees RC, Murray AK (1997) An immunohistochemical study of altered immunomodulatory molecule expression in head and neck squamous cell carcinoma. Br J Cancer 76:836PubMed

36.

Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA (2000) Human leucocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenic consequences. Clin Cancer Res 6:2794PubMed

37.

Hicklin DJ, Marincola FM, Ferrone S (1999) HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5:178PubMed

38.

Seliger B, Schreiber K, Delp K, Meissner M, Hammers S, Reichert T, Pawlischko K, Tampe R, Huber C (2001) Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. Tissue Antigens 57:39CrossRefPubMed

39.

Clyuyeva NG, Roskin GI (1963) Biotherapy of malignant tumours. Pergamon, Oxford

40.

Coudert J (1961) Clinical and experimental investigation on the effect of Trypanosoma cruzi extracts on certain forms of cancer. Antibiotiki 2:99

41.

Amiel JL, Sancho-Garnier H, Vanderbrouck C, Eschwege F, Droz JP, Schwaab G, Wilbault P, Stromboni M, Rey A (1979) First results of a randomized trial on immunotherapy of head and neck tumors. Recent Results Cancer Res 68:318

42.

Bier J, Rapp HJ, Borsos T (1981) Randomized study on intratumoral BCG-cell wall preparation (CWP) therapy in patients with squamous cell carcinoma in the head and neck. Immunotherapy 12:71

43.

Cheng VS, Suit HD, Wang CC, Raker J, Kaufman S, Rothman K, Walker A, Mcnulty P (1982) Clinical trial of Corynebacterium parvum (intra-lymph-node and intravenous) and radiation therapy in the treatment of head and neck carcinoma. Cancer 49:239PubMed

44.

Donaldson RC (1973) Chemoimmunotherapy for cancer of the head and neck. Am J Surg 126:507PubMed

45.

Richman SP, Livingston RB, Gutterman JU, Suen JY, Hersh EM (1976) Chemotherapy versus chemo-immunotherapy of head and neck cancer: report of a randomized study. Cancer Treatment Rep 60:535

46.

Taylor SG, Raynor WJJ, Bytell DE, Sisson GA (1983) A randomized trial of adjuvant BCG immunotherapy in head and neck cancer. Arch Otolaryngol 109:544PubMed

47.

Kitahara S, Ikeda M, Inouye T, Matsunaga T, Yamaguchi K, Takayama E, Healy GB, Tsukuda M (1996) Inhibition of head and neck metastasis and/or recurrent cancer by local administration of multi-cytokine inducer OK-432. J Laryngol Otol 110:449PubMed

48.

Olivari AJ, Pradier R, Califano L, Guardo A, Glait HM (1979) Levamisole in squamous cell carcinoma of the head and neck. Cancer Treatment Rep 63:983

49.

Rabinowich H, Vitolo D, Altarac S, Herberman RB, Whiteside TL (1992) Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells. J Immunol 149:340PubMed

50.

Sacchi M, Klapan I, Johnson JT, Whiteside TL (1991) Antiproliferative effects of cytokines on squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 117:321PubMed

51.

Cortesina G, De Stefani A, Giovarelli M, Barioglio MG, Cavallo GP, Jemma C, Forni G (1988) Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically. Cancer 62:2482PubMed

52.

Cortesina G, De Stefani A, Galeazzi E, Cavallo GP, Jemma C, Giovarelli M, Vai S, Forni G (1991) Interleukin-2 injected around tumor draining lymph nodes in head and neck cancer. Head Neck 13:125PubMed

53.

Mantovani G, Gebbia V, Airoldi M, Bumma C, Contu P, Bianchi A, Ghiani M, Dessi D, Massa E, Curreli L, Lampis B, Lai P, Mulas C, Testa A, Proto E, Cadeddu G, Tore G (1998) Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin. Cancer Immunol Immunother 47:149CrossRefPubMed

54.

Mattjijssen V, De Mulder PH, Schornagel JH et al (1991) Clinical and immunopathological results of a phase II study of perilymphatically injected recombinant interleukin-2 in locally far advanced, nonpretreated head and neck squamous cell carcinoma. J Immunother 10:63PubMed

55.

Vlock DR, Snyderman CH, Johnson JT, Myers EN, Eibling DE, Rubin JS, Kirkwood JM, Dutcher JP, Adams GL (1994) Phase Ib trial of the effect of peritumoral and intronodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial. J Immunother 15:134

56.

Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, Snyderman C, Johnson JT, Myers E, Herberman RB et al (1993) Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 53:5654

57.

Urba SG, Forastiere AA, Wolf GT, Amrein PC (1993) Intensive recombinant interleukin 2 and alpha interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer 71:2326PubMed

58.

Valone FH, Gandara DR, Deisseroth AB, Perez EA, Rayner A, Aronson FR, Luce J, Paradise C (1991) Interleukin-2, cisplatin and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Immunother 10:207PubMed

59.

Agarwala S, Vlock D, Johnson JT et al (1991) Phase II trial of interferon-alpha in locally recurrent or metastatic head and neck cancer: results of ECOG trial P-Z386. Proc Am Soc Clin Oncol 10:205

60.

Vlock DR, Johnson J, Myers E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R, Colao D (1991) Preliminary trial of non-recombinant interferon-alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 13:15PubMed

61.

Schrijvers D, Johnson J, Jiminez U, Gore M, Kosmidis P, Szpirglas H, Robbins K, Oliveira J, Lewensohn R, Schuller J, Riviere A, Arvay C, Langecker P, Jacob H, Cvitkovic E, Vokes E (1998) Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16:1054PubMed

62.

Shin DM, Khuri FR, Murphy B, Garden AS, Clayman G, Francisco M, Liu D, Glisson BS, Ginsberg L, Papadimitrakopoulou V, Myers J, Morrison W, Gillenwater A, Ang KK, Lippman SM, Goepfert H, Hong WK (2001) Combined interferon-alfa, 13-cis-retinoic acid, and alpha-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 19:3010PubMed

63.

Ikic D, Padovan I, Brodarec I, Knezevic M, Soos E (1981) Application of human leucocyte interferon in patients with tumours of the head and neck. Lancet 1:1025CrossRefPubMed

64.

Medenica R, Slack N (1985) Clinical results of leukocyte interferon-induced tumor regression in resistant human metastatic cancer resistant to chemotherapy and/or radiotherapy-pulse therapy schedule. Cancer Drug Deliv 2:53PubMed

65.

Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH (1990) Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg 116:1271PubMed

66.

Barrera JL, Verastegui E, Meneses A, Zinser J, delaGarza J, Hadden JW (2000) Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Arch Otolaryngol Head Neck Surg 126:345

67.

Meneses A, Verastegui E, Barrera JL, Zinser J, de la Garza J, Hadden JW (1998) Histologic findings in patients with head and neck squamous cell carcinoma receiving perilymphatic natural cytokine mixture (IRX-2) prior to surgery. Arch Pathol Lab Med 122:447PubMed

68.

Verastegui E, Barrera JL, Zinser J, Del Rio R, Meneses A, De La Garza J, Hadden JW (1997) A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer. Int J Immunopharmacol 19:619CrossRefPubMed

69.

Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495PubMed

70.

Vlock DR, Scalise D, Schwartz DR, Richter DE, Krause CJ, Baker SR, Carey TE (1989) Incidence of serum antibody reactivity to autologous head and neck cancer cell lines and augmentation of antibody reactivity following acid dissociation and ultrafiltration. Cancer Res 49:1361PubMed

71.

Vlock DR, Toporowicz A, Arnold B, Aul D, McCoy JP Jr, Carey TE, Brown WE (1993) Isolation and purification of a squamous cell carcinoma of the head and neck-associated antigen identified by autologous antibody. Biochem Biophys Acta 1181:174CrossRefPubMed

72.

Kimmel KA, Carey TE (1986) Altered expression in squamous carcinoma cells of an orientation restricted epithelial antigen detected by monoclonal antibody A9. Cancer Res 46:3614PubMed

73.

Van Waes C, Kozarsky KF, Warren AB, Kidd L, Paugh D, Liebert M, Carey TE (1991) The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Cancer Res 51:2395PubMed

74.

Brakenhoff RH, van Gog FB, Looney JE, van Walsum M, Snow GB, van Dongen GA (1995) Construction and characterization of the chimeric monoclonal antibody E48 for therapy of head and neck cancer. Cancer Immunol Immunother 40:191CrossRefPubMed

75.

Quak JJ, Balm AJM, Brakkee JPG, Scheper RJ, Meijer CJLM, Snow GB (1990) Production of monoclonal antibodies to squamous cell carcinoma antigens. Arch Otolaryngol Head Neck Surg 116:181PubMed

76.

Quak JJ, Van Dongen GAMS, Gerretsen M, Hayashida D, Balm AJM, Brakkee JPG, Snow GB, Meijer CJLM (1990) Production of monoclonal antibody (K931) to a squamous cell carcinoma antigen identified as the 17-1A antigen. Hybridoma 9:377PubMed

77.

Van Dongen GAMS, Brakenoff RM, Brink CT, Van Gog FB, De Bree R, Quak JJ, Snow GB (1996) Squamous cell carcinoma-associated antigens used in novel strategies for detection and treatment of minimal residual head and neck cancer. Anticancer Res 16:2409PubMed

78.

Van Hal NL, Van Dongen GA, Rood-Knippels EM, Van Der Valk P, Snow GB, Brakenhoff RH (1996) Monoclonal antibody U36, a suitable candidate for clinical immunotherapy of squamous-cell carcinoma, recognizes a CD44 isoform. Int J Cancer 68:520CrossRefPubMed

79.

Bergler W, Bier H, Ganzer U (1989) The expression of epidermal growth factor receptors in the oral mucosa of patients with oral cancer. Arch Otorhinolaryngol 246:121PubMed

80.

Bier H, Hoffmann T (1996) Epidermal growth factor receptor in head and neck squamous cell carcinomas. In: Werner JA, Lippert BM, Rudert HH (eds) Head and neck cancer—advances in basic research. Excerpta Medica Int Congress Ser 1114:225

81.

Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Bretlau P (1992) Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch Otorhinolaryngol 249:243PubMed

82.

Grandis JR, Melhem MF, Barnes EL, Tweardy DJ (1996) Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284CrossRefPubMed

83.

Bier H, Reiffen KA, Haas I, Stasiecki P (1995) Dose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinoma. Eur Arch Otorhinolaryngol 252:433PubMed

84.

Bier H, Hoffmann T, Hauser U, Wink M, Öchler M, Kovar A, Müser M, Knecht R (2001) Clinical trial with escalating doses of the anti-epidermal growth factor receptor humanized monoclonal antibody EMD 72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 47:519CrossRefPubMed

85.

Modjtahedi H, Hickish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C, Gore M (1996) Phase I trial and tumour localisation of the anti-EGFR monoclonal antibody ICR 62 in head and neck or lung cancer. Br J Cancer 73:228PubMed

86.

Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, D’Andrea G, Seidman A, Norton L, Gunnett K, Falcey J, Anderson V, Waksal H, Mendelsohn J (2000) Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 8:904

87.

Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW (2001) Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19: 3234PubMed

88.

Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, Lawhorn K, Khuri FR, Glisson BS, Myers J, Clayman G, Pfister D, Falcey J, Waksal H, Mendelsohn J, Hong WK (2001) Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204PubMed

89.

Bier H, Hoffmann T, van Lierop A (1998) Anti-(epidermal growth factor) receptor monoclonal antibodies for the induction of antibody-dependent cell-mediated cytotoxicity against squamous cell carcinoma lines of the head and neck. Cancer Immunol Immunother 46:167CrossRefPubMed

90.

Sung MW, Yasumura S, Johnson JT, Van Dongen GA, Whiteside TL (1995) Natural killer (NK) cells as effectors of antibody-dependent cytotoxicity with chimeric antibodies reactive with human squamous cell carcinoma of the head and neck. Int J Cancer 61:1PubMed

91.

Modjtahedi H, Affleck K, Stubberfield C, Dean C (1998) EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 13:335PubMed

92.

Monji M, Senju S, Nakatsura T, Yamada K, Sawatsubashi M, Inokuchi A, Nishimura Y (2002) Head and neck cancer antigens recognized by the humoral immune system. Biochem Biophys Res Commun 294:734CrossRefPubMed

93.

Colnot DR, Quak JJ, Roos JC, de Bree R, Wilhelm AJ, Snow GB, van Dongen GA (2001) Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck 23:559CrossRefPubMed

94.

Stroomer JW, Roos JC, Sproll M, Quak JJ, Heider KH, Wilhelm BJ, Castelijns JA, Meyer R, Kwakkelstein MO, Snow GB, Adolf GR, van Dongen GA (2000) Safety and biodistribution of 99mTechnetium-labeled anti-CD44v6 monoclonal antibody BIWA 1 in head and neck cancer patients. Clin Cancer Res 6:3046PubMed

95.

Dvorak HF, Nagy JA, Dvorak AM (1991) Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3:77PubMed

96.

Shockley TR, Lin K, Nagy JA, Tompkins RG, Dvorak HF, Yarmush ML (1991) Penetration of tumor tissue by antibodies and other immunoproteins. Ann N Y Acad Sci 618:367PubMed

97.

de Bree R, Kuik DJ, Quak JJ, Roos JC, van den Brekel MW, Castelijns JA, van Wagtendonk FW, Greuter H, Snow GB, van Dongen GA (1998) The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. Eur J Nucl Med 25:1562CrossRefPubMed

98.

Shibuya TY, Wei WZ, Zormeier M, Ensley J, Sakr W, Mathog RH, Meleca RJ, Yoo G, June CH, Levine B, Lum LG (1999) Anti-CD3/anti-CD28 monoclonal antibody-coated suture enhances the immune response of patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 125:1229PubMed

99.

Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313CrossRefPubMed

100.

Kienstra MA, Neel HB, Strome SE, Roche P (2003) Identification of NY-ESO-1, MAGE-1, and MAGE-3 in head and neck squamous cell carcinoma. Head Neck 25:457CrossRefPubMed

101.

Balz V, Scheckenbach K, Götte K, Bockmühl U, Petersen I, Bier H (2003) Is the p53 inactivation in squamous cell carcinomas of the head and neck understimated? Analysis of p53 Exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63:1188PubMed

102.

DeLeo AB (1998) p53-based immunotherapy of cancer. Crit Rev Immunol 18:29PubMed

103.

Offringa R, Vierboom MP, van der Burg SH, Erdile L, Melief CJ (2000) p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci 910:223PubMed

104.

Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL, DeLeo AB (1999) Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 5:1281PubMed

105.

Hoffmann TK, Nakano K, Elder E, Dworacki G, Finkelstein SD, Apella E, Whiteside TL, DeLeo AB (2000) Generation of T cells specific for the wild-type sequence p53_264-272 peptide in cancer patients: implications for immunoselection of epitope-loss variants. J Immunol 165:5938PubMed

106.

Röpke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, van der Burg S, Nijman HW, Melief CJM, Claesson MH (1996) Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a Wildtype p53-derived peptide. Proc Natl Acad Sci U S A 93:14704CrossRefPubMed

107.

Soussi T (1996) The humoral response to the tumor-suppressor gene product p53 in human cancer: implication for diagnosis and therapy. Immunol Today 17:353CrossRef

108.

Hoffmann TK, Meidenbauer N, Dworacki G, Kanaya H, Whiteside TL (2000) Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res 60:3542PubMed

109.

Hoffmann TK, Donnenberg AD, Finkelstein SD, Donnenberg VS, Friebe-Hoffmann U, Myers EN, Appella E, DeLeo AB, Whiteside TL (2002). Frequency of Tetramer+ T cells specific for the wild-type sequence p53264-272 peptide in the circulation of patients with head and neck cancer. Cancer Res 62:3521PubMed

110.

Hoffmann TK, Loftus DJ, Nakano K, Maeurer MJ, Chikamatsu K, Appella E, Whiteside TL, DeLeo AB (2002) The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264–272) epitope. J Immunol 168:1338PubMed

111.

Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB (2003) P53(110–124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 63:3675PubMed

112.

Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on human head and neck carcinoma. J Exp Med 186:785PubMed

113.

Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K (1998) A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 187:277PubMed

114.

Kass ES, Greiner JW, Kantor JA, Tsang KY, Guadagni F, Chen Z, Clark B, De Pascalis R, Schlom J, Van Waes C (2002) Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer. Cancer Res 62:5049

115.

Eura M, Ogi K, Chikamatsu K, Lee KD, Nakano K, Masuyama K, Itoh K, Ishikawa T (1995) Expression of the MAGE gene family in human head-and-neck squamous-cell carcinomas. Int J Cancer 64:304PubMed

116.

Katsura F, Eura M, Chikamatsu K, Oiso M, Yumoto E, Ishikawa T (2000) Analysis of individual specific cytotoxic T lymphocytes for two MAGE-3-derived epitopes presented by HLA-A24. Jpn J Clin Oncol 30:117CrossRefPubMed

117.

Iwaka T, Eura M, Fukiage T et al (1989) Adoptive immunotherapy by intraarterial infusion of ATLAK or allo-TLAK cells in patients with head and neck cancer. Gan To Kagaku Ryoho 16:1438PubMed

118.

Ishikawa T, Ikawa T, Eura M, Fukiage T, Masuyama K (1989) Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumor cells and recombinant interleukin-2. Acta Otolaryngol 107:346PubMed

119.

Squadrelli-Saraceno M, Rivoltini L, Cantu G, Ravagnani F, Parmiani G, Molinari R (1990) Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and interleukin-2. Tumori 76:566PubMed

120.

Kubota E, Katano M, Kurokawa H, Imamura H, Katsuki T, Yamamoto H, Hisatsugu T, Nagumo F, Tadano J (1993) Tumoricidal effect of human PBMC following stimulation with OK-432 and its application for locoregional immunotherapy in head and neck cancer patients. J Craniomaxillofac Surg 21:30PubMed

121.

To WC, Wood BG, Krauss JC, Strome M, Esclamado RM, Lavertu P, Dasko D, Kim JA, Plautz GE, Leff BE, Smith V, Sandstrom-Wakeling K, Shu S (2000) Systemic adoptive T-cell immunotherapy in recurrent and metastatic carcinoma of the head and neck: a phase 1 study. Arch Otolaryngol Head Neck Surg 126:1225PubMed

122.

Letessier EM, Sacchi M, Johnson JT, Herberman RB, Whiteside TL (1990) The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cell Immunol 130:446PubMed

123.

Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB (1988) Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 26:1PubMed

124.

Yasumura S, Hirabayashi H, Schwartz DR, Toso JF, Johnson JT, Herberman RB, Whiteside TL (1993) Human cytotoxic T cells lines with restricted specificity for squamous cell carcinoma of the head and neck. Cancer Res 53:1461PubMed

125.

Boscia R, Chen K, Johnson JT, Whiteside TL (1988) Evaluation of therapeutic potential of interleukin 2 expanded tumor-infiltrating lymphocytes in squamous cell carcinoma. Ann Otol Rhinol Laryngol 97:414PubMed

126.

Hald J, Rasmussen N, Claesson MH (1995) Tumour-infiltrating lymphocytes mediate lysis of autologous squamous cell carcinomas of the head and neck. Cancer Immunol Immunother 41:243CrossRefPubMed

127.

Lin WC, Yasamura S, Whiteside TL (1993) Transfer of interleukin 2 receptor genes into squamous cell carcinoma: modification of tumor cell growth. Arch Otolaryngol Head Neck Surg 119:1229PubMed

128.

O’Malley BW, Sewell DA, Li D, Kosai K, Chen S, Woo SLC (1997) The role of interleukin 2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 11:667CrossRefPubMed

129.

Wollenberg B, Kastenbauer E, Mundl H, Schaumberg J, Mayer A, Andratschke M, Lang S, Pauli C, Zeidler R, Ihrler S, Lohrs, Naujoks K, Rollston R (1999) Gene therapy-phase I trial for primary untreated head and neck squamous cell cancer (SCCHN) UICC stage II-IV with a single intratumoral injection of hIL-2 plasmids formulated in DOTMA/Chol. Hum Gene Ther 10:141CrossRefPubMed

130.

Myers JN, Yasumura S, Suminami Y, Hirabayashi H, Lin W, Johnson JT, Lotze MT, Whiteside TL (1996) Growth stimulation of human head and neck squamous cell carcinoma cell lines by interleukin 4. Clin Cancer Res 2:127PubMed

131.

Day KV, Li D, Liu S, Guo M, O’Malley BW Jr (2001) Granulocyte-macrophage colony-stimulating factor in a combination gene therapy strategy for head and neck cancer. Laryngoscope 111:801

132.

Lang S, Zeidler R, Mayer A, Reiman V, Wollenberg B, Kastenbauer E (1999) Targeting head and neck cancer by GM-CSF-mediated gene therapy in vitro. Anticancer Res 19:5335PubMed

133.

Qiu ZH, Wu CT, Lao MF, Pan LZ, Li YM (2002) Growth suppression and immunogenicity enhancement of Hep-2 or primary laryngeal cancer cells by adenovirus-mediated co-transfer of human wild-type p53, granulocyte-macrophage colony-stimulating factor and B7-1 genes. Cancer Lett 182:147CrossRefPubMed

134.

Gleich LL (2000) Gene therapy for head and neck cancer. Laryngoscope 110:708CrossRefPubMed

135.

Nikitina EY, Clark JI, van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI (2001) Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 7:127PubMed

136.

Mailliard RB, Egawa S, Cai Q, Kalinska A, Bykovskaia SN, Lotze MT, Kapsengerg ML, Storkus WJ, Kalinski P (2002) Complementary dendritic cell-activating function of CD8+ and CD4+ T cells: helper role of CD8+ T cells in the development of T helper type 1 responses. J Exp Med 195:473

137.

Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Mueller-Berghaus J, Kirkwood JM, Kwok WW, Storkus WJ (2002) Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma. J Exp Med 196:619

138.

Seliger B, Cabrera T, Garrido F, Ferrone S (2002) HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol 12:3CrossRefPubMed

139.

Vogl SE, Schoenfeld DA, Kaplan BH, Lerner HJ, Horton J, Creech RH, Barnes LE (1982) Methotrexate alone or with regional subcutaneous Corynebacterium parvum in the treatment of recurrent and metastatic squamous cancer of the head and neck. Cancer 50:2295PubMed

140.

Ferris RL, DeLeo AB, Whiteside TL (2003) Adjuvant p53 peptide loaded DC-based therapy of subjects with squamous cell cancer of the head and neck (a phase I safety and immunogenicity trial). UPCI Protocol, Pittsburgh

141.

De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G (1996) Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother Emphasis Tumor Immunol 19:125PubMed

142.

Vlock DR, Andersen J, Kalish LA, Johnson JT, Kirkwood JM, Whiteside T, Herberman RB, Adams GS, Oken MM, Haselow RE (1996) Phase II trial of interferon-alpha in locally recurrent or metastatic squamous cell carcinoma of the head and neck: immunological and clinical correlates. J Immunother Emphasis Tumor Immunol 19:433PubMed

143.

Gerretsen M, Quak JJ, Brakenhoff RH, Snow GB, van Dongen GA (1994) The feasibility of radioimmunotherapy of head and neck cancer. Oral Oncol 30B:82

144.

Schrijvers AH, Quak JJ, Uyterlinde AM, van Walsum M, Meijer CJ, Snow GB, van Dongen G (1993) MAb U36, a novel monoclonal antibody successful in immunotargeting of squamous cell carcinoma of the head and neck. Cancer Res 53:4383PubMed

145.

Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M (1996) The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56:4766PubMed

Title: Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck
Authors: Thomas K. Hoffmann
Henning Bier
Theresa L. Whiteside
Publication date: 01-12-2004
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 12/2004
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0530-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2004

CD4+ T cells kill Id+ B-lymphoma cells: FasLigand-Fas interaction is dominant in vitro but is redundant in vivo

Evidence for immune defects in breast and lung cancer patients

Cocultures of metastatic and host immune cells: selective effects of NAMI-A for tumor cells

Dendritic cell–tumor cell hybrid vaccination for metastatic cancer

Analysis of the autoantibody repertoire in Burkitt’s lymphoma patients: frequent response against the transcription factor ATF-2

Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop

Keynote webinar | Spotlight on antibody–drug conjugates in cancer